Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Larimar Therapeutics Inc (LRMR)

Larimar Therapeutics Inc (LRMR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Larimar Therapeutics Reports Positive Initial Data from Nomlabofusp OLE Study for Friedreich’s Ataxia Quiver Quantitative, Inc. - Mon Dec 16, 4:20PM CST

Larimar Therapeutics reports positive results from nomlabofusp study for Friedreich’s ataxia, showing increased frataxin levels and potential clinical benefits.Quiver AI SummaryLarimar Therapeutics announced...

LRMR : 4.01 (+0.75%)
Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich’s Ataxia GlobeNewswire - Mon Dec 16, 6:00AM CST

LRMR : 4.01 (+0.75%)
Larimar Therapeutics Presents Promising Data on Nomlabofusp at International Congress for Ataxia Research, Showing Potential to Enhance Frataxin Levels in Friedreich's Ataxia Patients Quiver Quantitative, Inc. - Mon Nov 18, 4:16PM CST

Nomlabofusp shows potential to improve frataxin levels and lipid profiles in Friedreich’s ataxia patients, with further studies planned.Quiver AI SummaryLarimar Therapeutics presented data on its treatment...

LRMR : 4.01 (+0.75%)
Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024 GlobeNewswire - Mon Nov 18, 6:00AM CST

LRMR : 4.01 (+0.75%)
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance Zacks Investment Research - Mon Nov 11, 7:52AM CST

For Immediate ReleaseChicago, IL – November 11, 2024 – Today, Zacks Equity Research like Madrigal Pharmaceuticals MDGL, Corcept Therapeutics CORT, Catalyst Pharmaceuticals CPRX, Larimar Therapeutics...

CORT : 51.40 (+0.49%)
TBPH : 9.59 (-1.44%)
MDGL : 308.44 (+5.12%)
LRMR : 4.01 (+0.75%)
CPRX : 21.27 (-0.89%)
5 Small Drug Stocks to Buy as Trump Gets Re-Elected
5 Small Drug Stocks to Buy as Trump Gets Re-Elected Zacks Investment Research - Fri Nov 8, 7:30AM CST

The drug industry witnessed major policy changes during Joe Biden's four-year term as U.S. President, including the historic Inflation Reduction Act (“IRA”). With Donald Trump’s reelection, the biotech...

CORT : 51.40 (+0.49%)
TBPH : 9.59 (-1.44%)
MDGL : 308.44 (+5.12%)
LRMR : 4.01 (+0.75%)
CPRX : 21.27 (-0.89%)
Larimar: Q3 Earnings Snapshot AP - Wed Oct 30, 6:29AM CDT

Larimar: Q3 Earnings Snapshot

LRMR : 4.01 (+0.75%)
Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results GlobeNewswire - Wed Oct 30, 6:00AM CDT

LRMR : 4.01 (+0.75%)
Larimar: Q2 Earnings Snapshot AP - Wed Aug 7, 6:20AM CDT

Larimar: Q2 Earnings Snapshot

LRMR : 4.01 (+0.75%)
2 Potentially High-Reward Growth Stocks to Buy Right Now Motley Fool - Wed May 29, 7:45AM CDT

These two biotechnology stocks could be gearing up for a run.

RNA : 31.82 (+2.48%)
LRMR : 4.01 (+0.75%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads Barchart - Sat Dec 21, 9:15AM CST
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot